A Prospective Study of Circulating Tumor DNA Detection in Surveillance for Lung Cancer Patients

Shenzhen Gene Health Bio Tech Co., Ltd.1 site in 1 country500 target enrollmentMay 3, 2017

ConditionsLung Neoplasms

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Lung Neoplasms
Sponsor: Shenzhen Gene Health Bio Tech Co., Ltd.
Enrollment: 500
Locations: 1
Primary Endpoint: Effect of surgery on ctDNA of lung cancer patients
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Conduct a prospective study to detect the change of ctDNA of surgical lung cancer patients.

Detailed Description

Studies have shown the feasibility of detecting mutation status by blood circulating tumor DNA (ctDNA) in lung cancer patients. The investigators plan to test the blood ctDNA in surveillance of surgical lung cancer patients. And evaluate the correlation between ctDNA level with tumor relapse or metastasis.

Registry

clinicaltrials.gov

Start Date

May 3, 2017

End Date

March 18, 2020

Last Updated

8 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Shenzhen Gene Health Bio Tech Co., Ltd.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Aged 18 to 80 years Undergo radical surgery Histologically confirmed diagnosis of lung cancer Considered primary lung cancer by clinical criteria Patients must have given written informed consent